Introduction {#s1}
============

In bacterial cells, the related AddAB and RecBCD enzymes are helicase-nuclease complexes responsible for initiating homologous recombination from double-stranded DNA breaks (DSBs). This activity underpins many key DNA transactions including DSB repair, phage restriction, and conjugal or transductional recombination ([@bib16]; [@bib42]).

Several observations suggest that selective inhibition of AddAB/RecBCD could be useful in biotechnology and medical applications. For example, they are important for the infectivity and pathogenicity of bacteria that need to resist oxidative and nitrosative attack from neutrophils and macrophages ([@bib3]; [@bib14]; [@bib4]; [@bib7]). They protect cells from antibacterials that cause DSBs, such as ciprofloxacin, because they afford a basal level of protection against such damage ([@bib4]; [@bib20]; [@bib19]; [@bib38]; [@bib27]). Moreover, the repair of such DSBs stimulates mutagenesis and recombination via both SOS-dependent and --independent mechanisms which may enhance the acquisition of antibacterial resistance ([@bib26]; [@bib8]). Finally, RecBCD activity interferes with RecET- and Redαβ-mediated 'recombineering', and so efficient bacterial genome engineering may require a *recBC* genetic background ([@bib11]; [@bib15]; [@bib45]; [@bib31]).

Many phage-encoded proteins manipulate host cell metabolism in order to promote phage replication and lysis ([@bib25]). For example, phage λ Gam is a potent inhibitor of the *Escherichia coli* RecBCD complex that helps to protect the phage DNA from degradation ([@bib35]; [@bib28]). In this work, we present the structure of Gam bound to RecBCD unveiling an inhibition mechanism based on protein mimicry of a DSB. We also show that *E. coli* and *Klebsiella pneumoniae* cells expressing Gam are hypersensitive to ciprofloxacin. Moreover, inhibition of RecBCD can restore susceptibility to laboratory-selected mutants and clinical isolates of *K. pneumoniae* that are fluoroquinolone resistant. More generally, we argue that the study of other phage-encoded DNA mimics will help to identify novel antibiotic targets and new mechanisms for target inhibition.

Results {#s2}
=======

Gam interacts with the DNA-binding site of RecBCD {#s2-1}
-------------------------------------------------

The Gam protein exists in two isoforms called GamL and GamS which differ in length ([@bib35]). Previous work has shown that GamS inhibits RecBCD by competing with DNA binding ([@bib12]; [@bib30]). The structure we present here, of the GamS dimer complexed with RecBCD, was determined by cryo-electron microscopy at 3.8 Å resolution ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}, [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"} and [2](#fig1s2){ref-type="fig"}, [Video 1](#media1){ref-type="other"}). It reveals that the GamS protein does indeed act as a steric block to the binding of DNA ([Figure 1](#fig1){ref-type="fig"}). The interaction with the duplex DNA-binding 'arm' of the RecB subunit is extensive and overlaps completely with that of the duplex DNA binding site ([Figure 1](#fig1){ref-type="fig"} and [Video 2](#media2){ref-type="other"}). Furthermore, one of the long N-terminal helical extensions of GamS inserts deeply into RecBCD. It occupies a channel that normally accommodates the nascent 3'-ssDNA tail bound to the RecB helicase subunit, increasing the extent of the steric block ([Figure 1](#fig1){ref-type="fig"}). Although the structure of the RecBCD complex is closest to that of the initiation complex ([@bib37]) it responds to the binding of Gam by small changes in conformation. The 2B and C-terminal domains of the RecC subunit together with the 2B domain of RecB move as a unit away from the RecB helicase domains. The RecD subunit is also much more flexible.10.7554/eLife.22963.002Figure 1.The overall structure of the RecBCD/Gam complex.(**A**) Surface representation of the electron density with a ribbon representation of the RecBCD subunits and the GamS protein dimer. (**B**) Cut away of the molecular surface of the RecBCD part of the model with the GamS dimer overlaid showing how the protein enters and fills the channel normally occupied by the 3'ssDNA tail. (**C**) The same view with the electron density for the GamS dimer overlaid.**DOI:** [http://dx.doi.org/10.7554/eLife.22963.002](10.7554/eLife.22963.002)10.7554/eLife.22963.003Figure 1---source data 1.EM data statistics and Final model.**DOI:** [http://dx.doi.org/10.7554/eLife.22963.003](10.7554/eLife.22963.003)10.7554/eLife.22963.004Figure 1---figure supplement 1.Electron microscopy information.(**A**) Typical micrograph of RecBCD/GamS complex particles. (**B**) A selection of 2D classes during refinement. (**C**) Local resolution map of the final reconstruction. (**D**) Gold standard FSC correlation curve.**DOI:** [http://dx.doi.org/10.7554/eLife.22963.004](10.7554/eLife.22963.004)10.7554/eLife.22963.005Figure 1---figure supplement 2.Representation of the local resolution of the GamS~1~ N-terminal helix for the deposited map compared to the same region in the maps of each of the three sub-classes.For each, only the extent of the map within 2.5 Å of the region of interest was displayed over the final refined coordinates (black), with all maps contoured to the same level in Chimera (0.04). ResMap was used to colour the surface of each map according to the local resolution as outlined by the scale bar. The three sub-classes were the major classes observed when the full dataset was re-classified using 3D classification without alignment as described in Materials and methods, with the resulting percentage distributions and final refined resolution limits indicated.**DOI:** [http://dx.doi.org/10.7554/eLife.22963.005](10.7554/eLife.22963.005)Video 1.Electron density map.A region of the electron density is shown in the location of the N-terminal helix of the Gam subunit that is located in the ssDNA binding site of the RecB subunit. Side chain density is clearly visible.**DOI:** [http://dx.doi.org/10.7554/eLife.22963.006](10.7554/eLife.22963.006)10.7554/eLife.22963.006Video 2.Overlay of the DNA substrate and the GamS dimer bound to RecBCD.**DOI:** [http://dx.doi.org/10.7554/eLife.22963.007](10.7554/eLife.22963.007)10.7554/eLife.22963.007

The crystal structure of the GamS protein alone ([@bib12]) revealed a pattern of negative charges on the surface that mimicked a DNA duplex, suggesting that molecular mimicry might be involved in binding. Consistent with this idea, a series of acidic side chains on Gam are located in positions equivalent to the phosphates of the DNA backbone and interact with many of the same residues on the RecBCD surface ([Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). However, the interaction of RecBCD with GamS is much more extensive than with duplex DNA ([Figure 2A and B](#fig2){ref-type="fig"}). The interactions of the N-terminal helix with the ssDNA channel are less similar to those involved in ssDNA binding although there is some conservation of hydrophobic contacts across the site ([Figure 2C and D](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Instead, the main component of the interaction is simply a steric block; the helix makes a snug fit in the channel involving many more contacts than the equivalent contacts with ssDNA ([Video 3](#media3){ref-type="other"}). Overall, the interaction surface involves many contacts and covers approximately 2500 Å^2^ which explains why the interaction between the proteins is so tight ([@bib12]; [@bib30]).10.7554/eLife.22963.008Figure 2.Comparison of the RecBCD/Gam and RecBCD/DNA interfaces.(**A**) Cartoon representation of contacts between RecBCD and the duplex portion of bound DNA. RecB is in orange and RecC in cyan in all panels. Interactions involving main chain atoms are denoted as m/c. (**B**) The same interface but with the GamS dimer (shown in magenta and purple). The interaction is much more extensive than with DNA but contacts in common are shown in bold. (**C**) Contacts between RecBCD and the ssDNA tails of DNA. (**D**) The same interface but with the GamS dimer. Again the interactions are much more extensive but still include several residues in common (shown in bold).**DOI:** [http://dx.doi.org/10.7554/eLife.22963.008](10.7554/eLife.22963.008)10.7554/eLife.22963.009Figure 2---figure supplement 1.Space filling representations of the bound DNA substrate and GamS dimer with negative charges coloured in red.**DOI:** [http://dx.doi.org/10.7554/eLife.22963.009](10.7554/eLife.22963.009)10.7554/eLife.22963.010Figure 2---figure supplement 2.Aspects of molecular mimicry are shown in a comparison of the interactions in RecBCD/DNA complex with that of the RecBCD/Gam complex in the region of the 3'-tail of the DNA substrate.(**A**) Overlap of the ssDNA (pink) and N-terminal helix of Gam (magenta). (**B**) The same region as the box in (**A**) but with the RecB and DNA components shown and details of the interactions. (**C**) The same site but for Gam and RecB. Note that there is some mimicry of the hydrophobic stacking interactions in both complexes.**DOI:** [http://dx.doi.org/10.7554/eLife.22963.010](10.7554/eLife.22963.010)Video 3.Details of the interactions between the N-terminal helix of Gam and the RecB subunit.**DOI:** [http://dx.doi.org/10.7554/eLife.22963.011](10.7554/eLife.22963.011)10.7554/eLife.22963.011

*Escherichia coli* cells expressing Gam are hypersensitive to ciprofloxacin {#s2-2}
---------------------------------------------------------------------------

Quinolone antibacterials target DNA gyrase and topoisomerase IV and kill cells by stabilising covalent topoisomerase-DNA adducts to produce DSBs. Based on the sensitivity of *recBC* cells to quinolones ([@bib20]; [@bib19]; [@bib38]; [@bib27]) and the well-characterised role of RecBCD in the repair of DSBs ([@bib16]), we hypothesised that expression of Gam would potentiate the killing effects of ciprofloxacin. To test this hypothesis, we engineered pBAD plasmids to express the two isoforms of Gam (GamL and GamS) from an arabinose-inducible promoter. In the absence of ciprofloxacin, expression of Gam had no apparent effect on the viability of *E. coli MG1655* ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). We next compared the ciprofloxacin minimum inhibitory concentration (MIC) against *E. coli* cells either expressing Gam or containing an empty vector construct. In broth culture, expression of either GamS or GamL reduced the MIC by approximately four-fold compared to the control, and equivalent results were obtained using spot tests on agar plates ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The MIC potentiation effect was dependent on arabinose ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) and specific for quinolone-induced DSBs; equivalent experiments measuring the MIC for ampicillin showed no effect of Gam (data not shown). These experiments demonstrate, at the biochemical level, the synthetic lethality observed between topoisomerase malfunction and RecBCD in gene knockout studies ([@bib38]).10.7554/eLife.22963.012Figure 3.Inhibition of bacterial DSB repair potentiates fluoroquinolone antibiotics.(**A**) Ciprofloxacin minimum inhibitory concentration (MIC) assay against *E. coli* MG1655 cells in the presence or absence of Gam isoforms as indicated. Experiments were performed as described in the Materials and methods in the presence of arabinose to induce expression of the small or large isoforms of Gam. Control experiments were performed under identical conditions with the empty pBADK expression vector. (**B**) Disc susceptibility assays are standardised tests that quantify antibacterial susceptibility in terms of an inhibition zone diameter, and also classify bacterial strains as either resistant, or not resistant, to antibacterial agents based on expected drug efficacy in a clinical setting. The experiments were performed and interpreted in accordance with CLSI guidelines ([@bib9]) with a range of fluoroquinolones (CIP; ciprofloxacin, OFL; ofloxacin, NOR; norfloxacin, LEV, levoxofloxacin). Illustrative results for wild type *K. pneumoniae* (Ecl8) and a resistant strain (Ecl8-CIP-M2) are shown using the GamL isoform. Note that the magnification of the plates is different for the two strains as is apparent from the disc sizes. The inhibition zone diameters for all strains, with both GamL and GamS, are summarised in [Table 1](#tbl1){ref-type="table"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22963.012](10.7554/eLife.22963.012)10.7554/eLife.22963.013Figure 3---figure supplement 1.Spot tests for ciprofloxacin sensitivity on agar plates.(**A**) Spot tests show the viability of *E.coli* MG1655 at varying ciprofloxacin concentrations and in the presence of pBADK vectors expressing no protein (control), GamL or GamS as indicated and in the presence of 1% (w/v) arabinose. (**B**) The ciprofloxacin potentiation effect of Gam is arabinose-dependent. Experiments were performed at 4 ng/ml ciprofloxacin. Spot tests were performed by making five-fold serial dilutions of a \~10^5^ colony forming units (cfu)/ml starting culture of *E. coli* MG1655 and spot plating onto agar supplemented with kanamycin (50 ug/ml), arabinose (±1% w/v as indicated) and ciprofloxacin (as indicated).**DOI:** [http://dx.doi.org/10.7554/eLife.22963.013](10.7554/eLife.22963.013)

Inhibition of DSB repair reverses fluoroquinolone resistance in *K. pneumoniae*, including clinical isolates {#s2-3}
------------------------------------------------------------------------------------------------------------

*K. pneumoniae* is an important opportunistic human pathogen that causes a variety of infections and is of increasing concern due to the recent emergence of antibiotic resistant and hypervirulent strains ([@bib32]). To test whether Gam expression increased the susceptibility of wild type *K. pneumoniae* to fluoroquinolones, we used disc susceptibility testing to four different fluoroquinolones. These are standardised assays based on inhibition zone diameter values defined by the CLSI ([@bib9]) which classify bacterial strains as either resistant, or not resistant, to fluoroquinolones based on the expected efficacy of the drug in a clinical context. Five strains were used: the wild-type strain Ecl8, two laboratory-selected Ecl8 mutant derivatives having sequentially reduced ciprofloxacin susceptibility, and two *K. pneumoniae* clinical isolates. Ecl8, and the single-step reduced susceptibility mutant Ecl8-CIP-M1 are not clinically resistant to any of the four test fluoroquinolones regardless of Gam expression, although cells containing the phage protein are significantly *more* susceptible (i.e. the inhibition zone diameters are greater in all cases) confirming fluoroquinolone potentiation by Gam in this species ([Figure 3B](#fig3){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). The two-step mutant ECl8-CIP-M2 and clinical isolate R16 are classified as clinically resistant to all four test fluoroquinolones; isolate R20 is resistant to three of them. In all cases, expression of GamL increases fluoroquinolone susceptibility to a level that reverses clinical resistance. Whilst GamS generally had a smaller effect than GamL, it still reversed resistance in all but the least susceptible clinical isolate, R16 ([Table 1](#tbl1){ref-type="table"}).10.7554/eLife.22963.014Table 1.Disc susceptibility assay for *K. pneumoniae* Ecl8wt, derived mutants and clinical isolates expressing GamL or GamS from pBADK. The disc susceptibility assay were performed according to the CLSI protocol ([@bib9]) using Mueller-Hinton agar with 0.2% (w/v) arabinose to stimulate expression of cloned genes (in bracket) and 30 mg/L kanamycin to select for the pBADK plasmids. Resistance breakpoints are as set by the CLSI ([@bib9]). Values shaded designate resistance. Values reported are the means of three repetitions rounded to the nearest integer.**DOI:** [http://dx.doi.org/10.7554/eLife.22963.014](10.7554/eLife.22963.014)*K. pneumoniae* strainsDiameter of growth inhibition zone (mm) around fluoroquinolone discFluoroquinolone (µg in disc)Ciprofloxacin (5)Levofloxacin (5)Norfloxacin (10)Ofloxacin (5)Ecl8wt pBADK (Control)34323030Ecl8wt pBADK (GamL)40373737Ecl8wt pBADK (GamS)46424139Ecl8-CIP- M1 pBADK (Control)24212019Ecl8-CIP-M1 pBADK (GamL)31272424Ecl8-CIP-M1 pBADK (GamS)28272525Ecl8-CIP-M2 pBADK (Control)1412118Ecl8-CIP-M2 pBADK (GamL)21171614Ecl8-CIP-M2 pBADK (GamS)21181614R16 pBADK (Control)8886R16 pBADK (GamL)17161616R16 pBADK (GamS)15151512R20 pBADK (Control)15131411R20 pBADK (GamL)20191915R20 pBADK (GamS)18171715

Discussion {#s3}
==========

The recent work of DuBow and colleagues has elegantly demonstrated the potential for novel antibacterial discovery through the characterisation of bacteriophage:host interactions ([@bib25]). Indeed, phage have evolved a wide variety of strategies to repurpose host cell functions for their own benefit, including inhibition of key bacterial proteins. These include many examples of proteins that target DNA replication, recombination and repair factors, which often share the primary structure characteristics of DNA mimic proteins ([@bib40]). Characterisation of DNA mimic proteins provides an attractive route towards the identification and validation of novel antibiotic targets, because bacterial DNA transactions are not only crucial for survival but are structurally orthogonal to their eukaryotic counterparts ([@bib34]). Moreover, the systematic analysis of the antibiotic sensitivity of single gene knockouts in *E. coli* highlights the potential of targeting DNA binding proteins as part of 'co-antibacterial' strategies to potentiate the effects of existing drugs ([@bib38]).

In this work, we determined the structural basis for inhibition of the RecBCD complex by the phage-encoded DNA mimic Gam, and exploited this interaction to show that inhibition of host cell DSB repair is a useful co-antibacterial strategy alongside quinolone drugs. GamL reversed resistance to all four tested fluoroquinolones in clinical isolates of multi-drug resistant *K. pneumoniae*, a human pathogen, as defined by an assay validated to predict clinical efficacy of antibacterial drugs ([@bib9]). Our data show that the Gam protein works by blocking the DNA binding site, partly by imitating both the single- and double-stranded portions of broken DNA. Gam has also been reported to interact with the SbcCD complex, another nuclease implicated in DNA repair ([@bib22]). However, inhibition of SbcCD is unlikely to contribute to the antibacterial potentiation effect observed here, because cells lacking SbcCD activity are not sensitive to ciprofloxacin ([@bib20]; [@bib1]; [@bib24]). DNA mimicry has been observed previously for phage-encoded proteins that target type I restriction endonucleases and glycosylases ([@bib21]; [@bib6]; [@bib10]) and it may be a common mechanism for bacteriophages to modulate DNA replication and repair in their hosts. Bacteriophage P22 codes for another, distinctive RecBCD inhibitor called Abc2 but this operates by a poorly-characterised mechanism ([@bib29]). Moreover, a small molecule inhibitor of AddAB/RecBCD (ML328) has recently been developed ([@bib5]). It will be of great interest to understand the inhibitory mechanisms of these molecules, expanding our understanding of how we can control bacterial DNA repair and, potentially, exploit this knowledge to combat antibacterial resistance.

Materials and methods {#s4}
=====================

Cloning of the bacteriophage λ Gam protein {#s4-1}
------------------------------------------

For over-expression in *E. coli*, the gene encoding bacteriophage lambda GamS, corresponding to residues 41--138 of the full-length Gam protein, was synthesised with codon optimisation for *E.coli* expression (GeneArt, Thermo Fisher, Waltham, MA, USA). GamS was cloned into pET22b, between NdeI and BamHI, using In-Fusion cloning. For fluoroquinolone potentiation studies, the genes encoding GamS and full length GamL were cloned into the pBAD322K plasmid (which replicates in both *E. coli* and *K. pneumoniae*) under the control of an arabinose-inducible promoter (a gift from Prof. John Cronan, University of Illinois \[[@bib13]\]) using the NcoI and HindIII restriction sites. All plasmid sequences were verified by direct DNA sequencing.

Expression and purification of the RecBCD-Gam complex {#s4-2}
-----------------------------------------------------

GamS protein was over-expressed using the pET22b construct in BL21 (DE3) cells with 4 hr induction at 27°C. The purification procedure for GamS was as described ([@bib12]). As observed previously, GamS purifies as a dimer. *E. coli* RecBCD complex was expressed and purified as described ([@bib43]). A 2:1 molar excess of dimeric GamS was incubated with RecBCD for 15 min at room temperature prior to size-exclusion chromatography with a Superdex 75 10/300 GL column, to separate free GamS. The buffer used contained: 25 mM Tris pH 7.5, 50 mM NaCl and 0.5 mM TCEP (pH 7.0). The peak fractions were pooled and concentrated to 1.4 mg/ml using Vivaspin 30 KDa molecular weight cut-off centrifugal concentrators.

Cryo-electron microscopy grid preparation and data collection {#s4-3}
-------------------------------------------------------------

Thinned C-flat 1 × 1 µm holey carbon film grids were prepared as described ([@bib43]). Grids were thinned using a total of 3 min of glow discharge (in 30 s steps), left for two weeks and then treated using a 1 mM solution of Amphipol A8-35. Sample (3 µL) was evenly applied to the grid before blotting and freezing in liquid ethane using a Vitrobot Mark IV (FEI). For blotting, a relative blot force of −4 for 1 s at 4°C was used. Data were collected using a Titan Krios I microscope operated at 300 KV at eBIC, Diamond, UK. Zero loss energy images were collected automatically using EPU (FEI) on a Gatan K2-Summit detector in counting mode with a pixel size corresponding to 1.34 Å at the specimen. A total of 358 images were collected with a nominal defocus range of −1.2 to −2.4 µm. Each image consisted of a movie stack of 25 frames with a total dose of 36 electrons/Å^2^ over 10 s corresponding to a dose rate of 6.5 electrons/pixel/s.

Data processing {#s4-4}
---------------

All 25 movie frames for each image stack were aligned and summed using Motioncorr ([@bib23]) prior to processing with Relion1.4 ([@bib36]). The actual defocus and other contrast transfer function (CTF) parameters for each summed movie stack were determined using Gctf ([@bib44]). Outlying micrographs were removed based on a number of criteria, leaving 334 images with Thon rings extending to an estimated resolution range from 6.2--2.8 Å (mean of 3.4 Å) and defocus range between −0.6 to −2.9 μm. The program Gautomatch ([@bib39]) was used for automated, template-free particle picking with a circular particle diameter of 140 Å, picking 134,124 particles. Initially, reference-free 2D classification was used to remove poor particles from autopicking, leaving 122,796 particles judged to represent potential protein complexes. These were subjected to 3D classification using the RecBCD:DNA crystal structure (PDB:1 W36) ([@bib37]), low-pass filtered to 45 Å, as a starting model. All four classes generated contained complexes of GamS with RecBCD although with different occupancy of the RecB nuclease and RecD 2A/2B domains. All particles were initially kept together for more robust classification after correcting for single-particle movement and per-frame radiation damage in particle polishing. 3D refinement of the 122,896 particles yielded a map with a resolution of 4.4 Å before masking (as estimated by the 'gold-standard' Fourier Shell Correlation (FSC) at the 0.143 cut-off criterion). After application of an auto-generated mask in Relion, the resolution of the map was 4.0 Å. Particle polishing improved the masked resolution to 3.8 Å.

At this point 3D classification without alignment ([@bib36]) was used to separate the different conformations within the data. The data were split into 10 classes with the majority (82%) falling into three major distinct classes. There were 30% of the particles in a class that lacked density for the RecB nuclease. The other two classes both represented the full complex with a similar spread of views but, when refined separately, showed slightly different conformations of a block of domains including the RecB 2B domain, part of the RecC CTD and the RecD 2A/2B domains. Since the GamS and surrounding structure was consistent for all three classes, they were summed for the final map at 3.8 Å. The final applied b-factor for sharpening used in post-processing was −70 Å^2^ with the resulting FSC plot shown in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.

Model building and refinement {#s4-5}
-----------------------------

Scripts for map conversion, cell matching and refinement in Refmac were kindly provided by Garib Murshudov (MRC-LMB). The recent cryo-EM structure of RecBCD in complex with DNA (PDB: 5LD2) ([@bib43]), and the crystal structure of GamS (PDB: 2UUZ) ([@bib12]), were used as starting models for global docking in Chimera ([@bib33]). Jelly-body Refmac refinement was used to correct for conformational changes in the model from the template structures. The entire model was carefully edited and fit using real-space refinement in Coot ([@bib17]) with occasional jelly-body refinement with Refmac, monitoring geometry statistics throughout. Near the end, phenix.real_space_refine ([@bib2]) was used to generate the final model, assign two group B-factors per residue and model statistics (see [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}).

Bacterial strains and fluoroquinolone sensitivity tests {#s4-6}
-------------------------------------------------------

Fluoroquinolone sensitivity was tested in *E. coli* MG1655 and five different strains of *K. pneumoniae;* wild-type isolate Ecl8 (a fully susceptible strain ([@bib18]) and a gift from Dr T. Schneiders, University of Edinburgh); Ecl8-CIP-M1, a mutant derivative selected for growth on LB agar containing 30 ng/mL of ciprofloxacin following plating of 100 µL of an overnight culture of Ecl8; Ecl8-CIP-M2, a mutant derivative selected for growth on LB agar containing 4 µg/mL of ciprofloxacin following plating of 100 µL of an overnight culture of Ecl8-CIP-M1; clinical isolates R16 and R20 selected because of their reduced ciprofloxacin susceptibility (cultured from the blood of patients being treated at Southmead Hospital, Bristol and a gift of Prof A. P. MacGowan). Minimum inhibitory concentration (MIC) assays were performed as described previously with some modifications ([@bib41]). Ciprofloxacin stocks of 4 µg/ml were made by dissolving in 0.1M HCl. Antibiotic serial dilutions were made in Mueller Hinton broth (MHB). For assays using *E. coli,* cells were grown in the absence of the inducer arabinose at 37°C to reach stationary phase. Cells were then diluted in MHB to OD~600~ \~10^−4^ or an approximate cell count of 10^5^ cfu.ml^−1^ within each well of a 96 well plate. The plates were incubated at 37°C for 18 hr. Where appropriate, the wells were supplemented with kanamycin (50 µg/ml), arabinose (1% w/v), and various antibiotics at the indicated concentrations. For *K. pneumoniae,* antibiotic susceptibility disc tests followed the CLSI protocol ([@bib9]). Media were supplemented with kanamycin (30 µg/ml) and arabinose (0.2% w/v) as appropriate. The zone of growth inhibition around each disc was determined, in triplicate, by taking multiple measurements of the diameter and quoting the mean value, rounded to the nearest integer.
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Thank you for submitting your article \"Structural basis for the inhibition of RecBCD by Gam and its synergistic antibacterial effect with quinolones\" for consideration by *eLife*. Your article has been favorably evaluated by Richard Losick (Senior Editor) and two reviewers, one of whom is a member of our Board of Reviewing Editors. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. Your covering letter should state how you have responded to the reviewer comments.

The manuscript extends the recent structure of RecBCD-DNA from the same group by presenting a new structure \[single-particle cryoEM\] of RecBCD complexed with the phage λ Gam protein that blocks access of DNA to RecBCD by being a DNA mimetic, thereby inhibiting DNA degradation by RecBCD. One might have guessed this a priori but nevertheless it is a nice structure. Importantly, the authors then go on to show that presence of Gam potentiates the effects of quinolone antibiotics in *E. coli* and a pathogenic *Klebsiella*, thereby showing potential for new antibacterials. Taken together a neat story; the paper is easy to read and follow, though the writing could be improved (see below), and the conclusions are supported by the data.

Specific comments:

1\) The whole manuscript feels as if written in a hurry and is somewhat \'ragged at the edges\'. It would benefit from careful editing.

2\) The authors should more clearly describe the difference (in amino acid sequence and other biochemical properties) between GamL and GamS. Do the authors have any idea why GamL has a stronger effect in vivo than GamS? It is a little bit non-ideal that the structural study used GamS instead of GamL given the stronger effect of GamL in vivo. Also, why did the authors choose to use the N-terminally truncated form of GamS (41-138)? Presumably removal of those residues might be required for crystallization, but probably not for cryoEM, so it would have been better to use the full-length protein?

3\) In the subsection "*Escherichia coli* cells expressing Gam are hypersensitive to ciprofloxacin" and later \[subsection "Cloning of the bacteriophage λ Gam protein"\]. pBAD plasmids are based on pBR322 and are *not* broad host range/specificity.

4\) [Figure 1](#fig1){ref-type="fig"} legend: \'major class\' -- not clear; in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} there are classes of 30%, 30% and 22%.

5\) Introduction, second paragraph: The protection must be because of the repair role of RecBCD. Why not state this explicitly?

6\) Discussion, last paragraph: Delete \'key\' -- it adds nothing.

7\) [Figure 1A](#fig1){ref-type="fig"} legend: Replace \'which\' by \'with\'.

8\) [Figure 3](#fig3){ref-type="fig"}. The designations \'not resistant\' or resistant seem a little over simplistic? E.g. in the bottom right panel \'less resistant\' would seem a more apt description?

9\) [Table 1](#tbl1){ref-type="table"} \'from\' not \'on\' pBADK.

10\) [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}. Almost illegible and \'offending\' typescript top left corner of top panel.

11\) It is worth mentioning in the Introduction, that Gam has also been shown to inhibit other nucleases in the cell. The authors should also consider in their analysis of the bacteria cell growth experiments whether any of the strains express these other nucleases, and whether it is possible some of the growth inhibition could result from these other activities.

10.7554/eLife.22963.017

Author response

*Specific comments:*

*1) The whole manuscript feels as if written in a hurry and is somewhat \'ragged at the edges\'. It would benefit from careful editing.*

We have tried to smooth out some of the rough edges in the revised version, not least of all by answering the reviewers' comments as below.

*2) The authors should more clearly describe the difference (in amino acid sequence and other biochemical properties) between GamL and GamS. Do the authors have any idea why GamL has a stronger effect in vivo than GamS? It is a little bit non-ideal that the structural study used GamS instead of GamL given the stronger effect of GamL in vivo. Also, why did the authors choose to use the N-terminally truncated form of GamS (41-138)? Presumably removal of those residues might be required for crystallization, but probably not for cryoEM, so it would have been better to use the full-length protein?*

The reviewers are confused about the relationship between GamS and GamL. GamS is a naturally occurring variant of GamL that is truncated at the N-terminus. It is actually rather difficult to make homogenous GamL because it gets truncated naturally during expression so is a mixture of GamS and GamL. In fairness, we do not know if this also applies to the in vivo experiments or even if the higher efficacy of GamL in vivo is due to higher expression levels or stability. Although, the reviewers are correct that the issues of a longer protein for crystallisation do not apply, a heterogeneous mixture is still not ideal for cryoEM. We therefore chose to use the GamS variant as we knew this would be homogeneous at the protein level as this still acts as an effective inhibitor. It may be that engineering the N-terminus to prevent proteolysis, or indeed increase efficacy of inhibition, would be effective but that is a whole project in itself.

*3) In the subsection "Escherichia coli cells expressing Gam are hypersensitive to ciprofloxacin" and later \[subsection "Cloning of the bacteriophage λ Gam protein"\]. pBAD plasmids are based on pBR322 and are not broad host range/specificity.*

The referees are correct to point out that pBADK is not a truly broad host range plasmid. However, the origin will replicate in many members of the family *Enterobacteriaceae*, including *K. pneumoniae* and *E. coli* that are used in this work. We have modified the text by removing the words "broad specificity" (Results) and "broad host range" (Methods). Instead we now simply point out in the Methods that pBADK can replicate in both of the organisms studied here.

4\) [Figure 1](#fig1){ref-type="fig"} legend: \'major class\' -- not clear; in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} there are classes of 30%, 30% and 22%.

"Major class of particles" now deleted from the legend.

*5) Introduction, second paragraph: The protection must be because of the repair role of RecBCD. Why not state this explicitly?*

As requested, we now state that protection against quinolones is due to DNA repair.

*6) Discussion, last paragraph: Delete \'key\' -- it adds nothing.*

The word "key" is now deleted.

*7) [Figure 1A](#fig1){ref-type="fig"} legend: Replace \'which\' by \'with\'.*

The word "which" replaced by "with".

*8) [Figure 3](#fig3){ref-type="fig"}. The designations \'not resistant\' or resistant seem a little over simplistic? E.g. in the bottom right panel \'less resistant\' would seem a more apt description?*

We understand the point the referees are making. It is of course the case that bacterial strains display a continuum of susceptibility levels to antibacterial agents which are condition-dependent, and the effect of Gam is to make all the strains we study more susceptible to quinolones regardless of whether they are classified as clinically resistant or not. However, in the context of the standardised disc susceptibility assays used here, the terms \"resistant\" and \"not resistant\" have a specific meaning related to clinical definitions of resistance in *Enterobacteriaceae* isolates. This is a binary definition based on empirical data from the US Clinical Laboratory Standards Institute that is used by clinicians to make antibiotic prescribing decisions, and the consensus in the AMR field is that the terms \"more resistant\" and \"less resistant\" should be avoided. The significance for our work is that, in principle, inhibition of DNA break repair in *K. pneumoniae* can restore the ability of fluoroquinolones to treat infections that would otherwise fail to respond to antibacterials. We have rewritten the relevant part of the Results section and the legend to [Figure 3](#fig3){ref-type="fig"} to clarify these points.

9\) [Table 1](#tbl1){ref-type="table"} \'from\' not \'on\' pBADK.

The word "on" replaced by "from" in [Table 1](#tbl1){ref-type="table"}.

*10) [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}. Almost illegible and \'offending\' typescript top left corner of top panel.*

Unfortunately, without "photoshopping" the image we can't get rid of the plate labelling or edge of the plates in the corner of the figures. However, this does at least show these are "real" data! However, we note that the abbreviation "cfu" was not defined and was a little small in the figure. Consequently, we have increased the font size and defined the term in the figure legend.

*11) It is worth mentioning in the Introduction, that Gam has also been shown to inhibit other nucleases in the cell. The authors should also consider in their analysis of the bacteria cell growth experiments whether any of the strains express these other nucleases, and whether it is possible some of the growth inhibition could result from these other activities.*

We thank the referees for this comment which we now directly address in the Discussion. We assume the nuclease in question is the SbcCD complex, which has been reported to be another interaction target of Gam. Inhibition of SbcCD is probably not important in the ciprofloxacin potentiation observed here because, somewhat surprisingly, at least three independent studies show that cells lacking SbcCD activity are not sensitive to ciprofloxacin.
